New York, New York (PRWEB) January 20, 2013
Actos bladder cancer lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. The next Status Conference in the Actos litigation has been scheduled for Thursday, January 24, 2013 at 10:30 a.m. According to an agenda posted on the Court’s website on January 16th, items to be discussed include the status of federal and state filings, as well as the status of discovery. (In re: Actos Product Liability Litigation, MDL No. 2299).
“We are pleased to see this litigation moving forward, as we continue to hear from Actos users who have been diagnosed with bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is currently offering free lawsuit evaluations to individuals who may have developed bladder cancer due to long-term use of Actos.
The U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer. * While Actos is still available in the U.S., the drug has been pulled from the market in Germany and France due to its association with bladder cancer.**
Actos lawsuits pending in the Western District of Louisiana allege that Takeda Pharmaceuticals and other Defendants concealed their knowledge that Actos could increase the risk for bladder cancer, and failed to provide adequate warnings to consumers and the health care community. According to court documents, the first trial in the federal Actos litigation is scheduled to begin on November 2014, followed by the second trial in July 2015.
Since June 2011, a number of additional studies have confirmed the association between long-term use of Actos and bladder cancer. In May 2012, research published in the British Medical Journal concluded that taking Actos for two years can double the risk of developing bladder cancer. *** A second study published in the Canadian Medical Association Journal in July 2012 concluded that patients taking Actos face a 22 percent increased risk of developing bladder cancer. ****
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
Read the full story at http://www.prweb.com/releases/actos-lawsuits/actos-bladder-cancer/prweb10340351.htm.
Copyright©2012 Vocus, Inc.
All rights reserved